Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in Colorectal Cancer
NCT03984578Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Jun 2019
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in colorectal cancer (CRC) (3 arms), sponsored by National Cancer Centre Singapore. Primary endpoints: Tumour immune gene expression signature, Pathology regression and 1 more. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03984578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984578.